Alireza Mansouri Highlights a Trial on Immunotherapy in Newly Diagnosed Glioblastoma
Alireza Mansouri, Associate Professor at Penn State Health, shared a post on LinkedIn about a paper by Andrew B Lassman et al. published on Journal of Clinical Oncology:
“Important Update Re clinical trials for glioblastoma: New Insights on Immunotherapy in Glioblastoma
Recent publication from the NRG Oncology BN007 trial
This study zeroed in on MGMT-unmethylated patients with newly diagnosed glioblastoma, aiming to see if adding dual immune checkpoint blockade (ipilimumab + nivolumab) to radiotherapy could offer promise compared to standard temozolomide.
It was designed as a randomized phase II/III trial, but unfortunately, it halted at phase II due to no promising signal – median progression-free survival was similar (7.7 months for immunotherapy vs. 8.5 for TMZ). No clear benefit observed.
That said, evaluation of specific molecular markers of response are still pending, and we eagerly await those results to guide future directions!
What are your thoughts on immunotherapy’s role in tough cases like this? Let’s discuss!”
Title: Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial
Authors: Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Andrew E. Sloan, Tony J.C. Wang, Kenneth D. Aldape, Jeffrey S. Wefel, Vinai Gondi, Alonso N. Gutierrez, Mohammed H. Manasawala, Mark R. Gilbert, Erik P. Sulman, Jedd D. Wolchok, Richard M. Green, Elizabeth C. Neil, Rimas V. Lukas, Samuel A. Goldlust, Matija Snuderl, Kristyn Galbraith, James J. Dignam, Minhee Won, Minesh P. Mehta
More posts featuring Alireza Mansouri on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023